Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies - Net Loss per Share (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Significant Accounting Policies
Potentially dilutive securities that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	46,607,200	8,414,167
Warrants
Significant Accounting Policies
Potentially dilutive securities that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	42,139,278	6,516,211
Stock options
Significant Accounting Policies
Potentially dilutive securities that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	127,000	27,000
Unvested restricted stock awards
Significant Accounting Policies
Potentially dilutive securities that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	3,742,676	1,251,072
Unvested restricted stock units
Significant Accounting Policies
Potentially dilutive securities that were excluded from the computation of diluted net loss per share, as they would be anti-dilutive	598,246	619,884